

SEP 22 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

9

Application Number

10/044,692

Filing Date

January 11, 2002

First Named Inventor

Thomas R. Cech, et al.

Art Unit

1642

Examiner Name

Susan NMN Ungar, Ph.D.


Attorney Docket Number

015389-002640US; 018/213C

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pages)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
Form PTO-1449 (1 page) with attached information (4 pages)		
Last page marker (1 page)		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Geron Corporation		
Signature			
Printed name	J. Michael Schiff		
Date	Sept 21/06	Reg. No.	40,253

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	Transmitted Sept 21/06 Pacific Time Sept 23/06 East Coast Time		
Typed or printed name			
		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

SEP 22 2006

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office
in accordance with 37 CFR § 1.6(d) on the date indicated.

Name _____

Date _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Thomas R. Cech et al.

Art Unit: 1642

Filing Date: January 11, 2002

Examiner: Susan N.M.N. Ungar, Ph.D.

Serial No: 10/044,692

Docket: 015389-002640
US; 018/213c

Title: NUCLEIC ACID VACCINE FOR ELICITING
AN IMMUNE RESPONSE AGAINST
TELOMERASE REVERSE TRANSCRIPTASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria VA 22313

Dear Sir,

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure. Included is a Declaration under 37 CFR § 1.56, listing related issued patents and pending applications owned or co-owned by Geron Corporation.

The Examiner is requested to consider whether any of the subject matter claimed in the patents and patent applications listed in the accompanying Declaration under 37 CFR § 1.56, or any of the prosecution history in the pending applications listed therein, is material to patentability of any claim in the present application.


PATENT
USSN 10/044,692
015389-002640US
018/213c

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, or that all relevant information has been found.

This Information Disclosure Statement is being filed after the first Office Action on the merits, but before a final Office Action or Notice of Allowance, pursuant to 37 CFR § 1.197(c)(2).

A fee under 37 CFR § 1.117(p) has already paid for information provided under 37 CFR § 1.56 since the last Office Action, and applicants respectfully submit that no additional fee is required for consideration of the enclosed information. However, in the event that the Office requires an additional fee, the Commissioner is hereby authorized to charge it to Deposit Account 07-1139.

Respectfully submitted,



J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

September 21, 2006

Form 1449 (modified)		Filing Date: January 11, 2002	U.S.S.N. 10/044,692
Information Disclosure Statement By Applicant		Inventors: T. Cech et al.	Docket: 018/213
		Title: Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase	Group: 1634 Examiner: Susan Ungar, Ph.D.

U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:
(none)						

Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref.	Jurisdiction	Document No.	Publication Date	Assignee:	Title:	Trans-lation
(none)							

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
	HA	Declaration under 37 CFR § 1.56 listing other issued patents and pending applications for telomerase reverse transcriptase.

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 1